November 12, 2025
Healthcare M&A gave markets the cleanest deal stories. Kimberly-Clark agreed to buy Kenvue in a cash-and-stock transaction valued at $48.7 billion. The combined company would own 11 brands with more than $1 billion of annual sales, including Kleenex, Cottonelle, Tylenol, and Listerine, with potential annual revenue around $32 billion. Kimberly-Clark offered $21.01 per Kenvue share, while Kenvue traded a little above $16 after the announcement. Kenvue rose 16%, but Kimberly-Clark fell 12%.
The split reaction was the story. Kimberly-Clark is buying scale, consumer-health exposure, and brand durability, but investors have to underwrite integration risk, the purchase price, and legal or reputational issues tied to Tylenol and Johnson's Baby Powder. That buyer-seller reaction is useful in recruiting because strategic logic and market approval are not always the same thing.
Metsera added a second healthcare angle. Pfizer was competing with Novo Nordisk for the weight-loss drug developer, with Pfizer's bid above $10 billion. Analysts expect the obesity-drug market to exceed $100 billion by 2030, and Metsera has at least eight potential drugs in the category. Its lead candidate is a monthly injection that showed about 14% more weight loss than placebo in early trials. Pfizer sued after Novo made a higher unsolicited offer.
Policy also supported GLP-1 demand. A new agreement with Eli Lilly and Novo Nordisk would let Medicare cover GLP-1 obesity drugs for the first time beginning in mid-2026. Medicare and Medicaid would pay $245 per month, while eligible Medicare patients would have $50 monthly copays for drugs such as Zepbound and Wegovy. Lilly said the agreement could open access to as many as 40 million Medicare patients.
AI infrastructure remained a major capital sink. OpenAI and AWS announced a seven-year cloud services deal worth about $38 billion, using AWS infrastructure and Nvidia GPUs. Amazon rose about 5% to record highs after the announcement, while the market still questioned how much long-term AI revenue can justify multi-trillion-dollar spending plans.
Valuation risk was also visible. The Shiller P/E moved above 40 for only the second time in history, and Palantir fell 8% despite 63% revenue growth to $1.18 billion and $476 million of net income because shares were trading near 230 times forward earnings. Tariffs had not broken the economy, but the Treasury was on pace to collect about $34 billion in October, and the delayed cost pass-through still mattered.